COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Phase 1, Open Label, Multicenter, Dose Escalation Study of YTB323 in Adult Patients with CLL/SLL and DLBCL

Protocol No
NOVARTIS-YTB323A12101
Principal Investigator
Nirav Shah
Phase
I
Summary
The purpose of the study is to find out the optimal dose of an engineered T cell Therapy and to determine if this therapy is safe.
Description
YTB323 (CD19-specific CAR-T Cells) in patients with CLL/SLL and DLBCL
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL